shutterstock_723391945_sean_pavone
Sean Pavone / Shutterstock.com
23 May 2019Big Pharma

City of Baltimore accuses Janssen of delaying generics

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
25 April 2019   A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.

More on this story

Generics
25 April 2019   A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.

More on this story

Generics
25 April 2019   A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.